SCF API DEVELOPMENT PIPELINE FOR INDEVIRATE
Phase 2 Deliverable: Bioactive Compound Extraction & SCF Analysis
1. Phase 2 Objective
To extract, isolate, and mechanistically map bioactive compounds from Phase 1–selected ethnobioprospecting sources and assign SCF functional roles across the five principles:
- Targeted Drug Action
- Pharmacokinetic Optimization
- Metabolic Efficiency
- Resistance Prevention
- Safety Profile
This phase operationalizes:
- Molecule isolation from prioritized botanical/fungal sources
- MoA (Mode of Action) and MeA (Mechanism of Action) assignment
- SCF role classification
- Preliminary pharmacokinetic and metabolic profiling
as defined in the SCF extraction protocol.
2. Input from Phase 1
Primary Lead Lineage: Cordycepin-based antiviral analog track
Comparator Lineages:
- Petiveria alliacea (sulfur compounds)
- Uncaria tomentosa (oxindole alkaloids)
- Tabebuia impetiginosa (lapachol/quinones)
3. Step 2.1 — Extraction Strategy & Method Selection
3.1 Extraction Matrix
Source | Target Compound Class | Solvent System | Extraction Method |
Cordyceps spp. (Amazon strains) | Nucleoside analogs (cordycepin) | Water / ethanol | Ultrasonic-assisted extraction + HPLC purification |
Petiveria alliacea | Sulfur compounds | Ethanol / methanol | Soxhlet extraction + GC-MS fractionation |
Uncaria tomentosa | Oxindole alkaloids | Acidified ethanol | Alkaloid extraction + preparative chromatography |
Tabebuia impetiginosa | Quinones (lapachol) | Hexane / ethyl acetate | Solvent partitioning + HPLC purification |
These selections align with polarity-based extraction rules for phytochemicals.
4. Step 2.2 — Molecule Identification & Isolation
4.1 Lead Compound Panel
Source | Lead Molecule | Chemical Class | Preliminary Relevance |
Cordyceps spp. | Cordycepin (3′-deoxyadenosine) | Nucleoside analog | Direct antiviral scaffold candidate |
Petiveria alliacea | Dibenzyl trisulfide | Organosulfur compound | Resistance-modulating co-agent |
Uncaria tomentosa | Mitraphylline / Isomitraphylline | Oxindole alkaloids | Immune modulation |
Tabebuia impetiginosa | Lapachol | Naphthoquinone | Viral enzyme interference hypothesis |
5. Step 2.3 — MoA & MeA Profiling
5.1 Mechanistic Assignment Table
Molecule | Mode of Action (MoA) | Mechanism of Action (MeA) | SCF Relevance |
Cordycepin | DNA/RNA targeting | Premature chain termination, RNA synthesis inhibition | Core antiviral scaffold |
Dibenzyl trisulfide | Enzyme modulation | Redox disruption, thiol interaction | Resistance suppression |
Mitraphylline | Immune modulation | NF-κB inhibition, cytokine regulation | Host-pathway stabilization |
Lapachol | Enzyme inhibition | Redox cycling, topoisomerase interference | Viral processing disruption |
MoA/MeA classification follows SCF-defined categories: receptor binding, enzyme inhibition, nucleic acid targeting, and signaling modulation.
6. Step 2.4 — SCF Functional Role Assignment
6.1 SCF Role Mapping
Molecule | SCF Role | Functional Description |
Cordycepin | Target Modulator (F1) | Direct viral replication arrest |
Dibenzyl trisulfide | Resistance Preventer (F5) | Multi-pathway redox pressure |
Mitraphylline | Safety Harmonizer (F2) | Immune stabilization, toxicity buffering |
Lapachol | Secondary Target Modulator (F3) | Auxiliary viral enzyme disruption |
This aligns with SCF role categories: target modulation, safety harmonization, metabolic regulation, absorption enhancement, and resistance prevention.
7. Step 2.5 — SCF Five-Axis Analysis
7.1 Multi-Axis Evaluation Table
Molecule | Targeted Action | PK Optimization | Metabolic Efficiency | Resistance Prevention | Safety Profile |
Cordycepin | High | Moderate (rapid metabolism risk) | Moderate | High (multi-target RNA disruption) | Moderate |
Dibenzyl trisulfide | Moderate | Moderate | Moderate | High | Moderate |
Mitraphylline | Moderate | Moderate | High | Moderate | High |
Lapachol | Moderate | Low–Moderate | Moderate | Moderate | Low–Moderate |
8. Step 2.6 — Pharmacokinetic & Metabolic Profiling
8.1 Preliminary PK Characteristics
Molecule | Absorption | Distribution | Metabolism | Key Limitation |
Cordycepin | Moderate | Systemic | Rapid deamination | Short half-life |
Dibenzyl trisulfide | Moderate | Lipophilic tissue | Hepatic metabolism | Stability variability |
Mitraphylline | Moderate | Immune tissues | CYP-mediated | Drug interaction potential |
Lapachol | Low–Moderate | Wide | Redox metabolism | Toxicity risk |
8.2 Optimization Requirements
- Cordycepin → Prodrug engineering or nanoparticle delivery
- Lapachol → Toxicity attenuation and targeted delivery
- Sulfur compounds → Stability enhancement
- Alkaloids → CYP interaction minimization
These align with SCF pharmacokinetic optimization strategies.
9. Step 2.7 — Preliminary SCF Synergy Architecture
9.1 Functional Synergy Matrix
Role | Molecule | Contribution |
Primary Antiviral | Cordycepin | Viral genome arrest |
Resistance Barrier | Dibenzyl trisulfide | Prevents adaptive escape |
Host Stabilizer | Mitraphylline | Reduces inflammatory drift |
Auxiliary Disruptor | Lapachol | Multi-target viral pressure |
9.2 Early Synergy Hypothesis
1 + 1 ⇒ 3 augmentation logic:
- Cordycepin (viral arrest)
- Dibenzyl trisulfide (resistance pressure)
→ Enhanced viral suppression beyond additive effect
10. Phase 2 Outcome
10.1 Confirmed Lead Candidate
Indevirate Lead Scaffold Direction:
Cordycepin-derived nucleoside analog backbone for integrase-adjacent viral genome disruption
10.2 Supporting Molecular Stack
- Sulfur compounds → resistance prevention
- Oxindole alkaloids → immune stabilization
- Quinones → auxiliary viral interference
10.3 Key Risks Identified
- Cordycepin metabolic instability
- Quinone toxicity
- Alkaloid CYP interactions
10.4 Advancement Criteria to Phase 3
Proceed if:
- Cordycepin analogization improves half-life
- Combination shows non-antagonistic synergy
- Safety thresholds acceptable in vitro
11. Phase 2 Conclusion
Phase 2 successfully:
- Extracted and identified four primary bioactive classes
- Established mechanistic mapping (MoA/MeA)
- Assigned SCF functional roles
- Completed five-axis SCF evaluation
- Defined Indevirate scaffold direction
Indevirate is now molecularly anchored to a cordycepin-derived antiviral scaffold with multi-agent SCF support architecture.
Next Sequential Output
Phase 3 — Synergy Metrics Computation (TSSM, HSV-F², SV-EQ, MGIS, SPCI)
Master Registry Index
SCF-HIV-AET-DP-0001 — AETERNAVIR Development Program
SCF-ETHBIO-WF-0001 — Ethnobioprospecting Workflow
SCF-ABMD-DB-0001 — Amazon Basin Medicinal Species Database
SCF-AMPA-0300 — Amazon Multi-Omic Pathway Atlas
SCF-SEF-MD-0001 — Synergistic Evaluation Framework
SCF-POT-FORM-0001 — SCF Potency Formula
SCF-REG-HIV-INDEVIRATE-P2-0001 — Indevirate Phase 2 Extraction & SCF Analysis Deliverable